Alprazolam Tablets, USP, 0.5mg, CIV, packaged in: a) 100-count bottle (NDC 51991-0705-01), b) 500-count bottle (NDC 51991-0705-05) and c) 1,000-count bottle (NDC 51991-0705-10), Rx only, Manufactured by Centaur Pharmaceuticals PVT. LTD., Hinjewadi, Pune, INDIA, Distributed by: Breckenridge Pharmaceuticals, Inc., Berlin, CT 06037.
Published March 22, 2023 · Recall initiated: March 2, 2023
Summary
FDA records drug Class II recall D-0459-2023, published March 22, 2023 and initiated March 2, 2023. Recalling firm: Breckenridge Pharmaceutical, Inc; Status: Terminated; Reported quantity: N/A; Lot: Lot # a) 5210673, exp. date 3/31/2023; 5210901, exp. date 5/31/2023; 5211461, exp. date 9/30/2024; 5220291, exp. date 2/28/2025; 5220559, exp. date 5/31/2025; b) 5210650, exp. date 3/31/2023, 5210651, exp. date 3/31/2023 5210652, exp. date 3/31/2023 5210653, exp. date 3/31/2023 5210674, exp. date 3/31/2023 5210732, exp. date 3/31/2023 5210733, exp. date 4/30/2023 5210753, exp. date 4/30/2023 5210902, exp. date 5/31/2023 5210903, exp. date 5/31/2023 5210904, exp. date 5/31/2023 5211231, exp. date 7/31/2023 5211281, exp. date 7/31/2024 5211282, exp. date 7/31/2024 5211283, exp. date 7/31/2024 5211284, exp. date 7/31/2024 5211336, exp. date 7/31/2024 5211337, exp. date 8/31/2024 5211338, exp. date 8/31/2024 5211462, exp. date 9/30/2024 5211463, exp. date 9/30/2024 5211464, exp. date 9/30/2024 5211465, exp. date 9/30/2024 5211516, exp. date 9/30/2024 5211644, exp. date 10/31/2024 5211645, exp. date 10/31/2024 5211690, exp. date 10/31/2024 c) 5210675, exp. date 3/31/2023 5210777, exp. date 4/30/2023 5210778, exp. date 4/30/2023 5210996, exp. date 5/31/2023 5211077, exp. date 6/30/2023 5211078, exp. date 6/30/2023 5211079, exp. date 6/30/2023 5211080, exp. date 6/30/2023 5211364, exp. date 8/31/2024 5211365, exp. date 8/31/2024 5211367, exp. date 8/31/2024 5211366, exp. date 8/31/2024 5211575, exp. date 10/31/2024 5211576, exp. date 10/31/2024 5211694, exp. date 11/30/2024 5220066, exp. date 12/31/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Potential risk of Cross Contamination
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Breckenridge Pharmaceutical, Inc
- Distributor
- USA nationwide.
- Lot
- Lot # a) 5210673, exp. date 3/31/2023; 5210901, exp. date 5/31/2023; 5211461, exp. date 9/30/2024; 5220291, exp. date 2/28/2025; 5220559, exp. date 5/31/2025; b) 5210650, exp. date 3/31/2023, 5210651, exp. date 3/31/2023 5210652, exp. date 3/31/2023 5210653, exp. date 3/31/2023 5210674, exp. date 3/31/2023 5210732, exp. date 3/31/2023 5210733, exp. date 4/30/2023 5210753, exp. date 4/30/2023 5210902, exp. date 5/31/2023 5210903, exp. date 5/31/2023 5210904, exp. date 5/31/2023 5211231, exp. date 7/31/2023 5211281, exp. date 7/31/2024 5211282, exp. date 7/31/2024 5211283, exp. date 7/31/2024 5211284, exp. date 7/31/2024 5211336, exp. date 7/31/2024 5211337, exp. date 8/31/2024 5211338, exp. date 8/31/2024 5211462, exp. date 9/30/2024 5211463, exp. date 9/30/2024 5211464, exp. date 9/30/2024 5211465, exp. date 9/30/2024 5211516, exp. date 9/30/2024 5211644, exp. date 10/31/2024 5211645, exp. date 10/31/2024 5211690, exp. date 10/31/2024 c) 5210675, exp. date 3/31/2023 5210777, exp. date 4/30/2023 5210778, exp. date 4/30/2023 5210996, exp. date 5/31/2023 5211077, exp. date 6/30/2023 5211078, exp. date 6/30/2023 5211079, exp. date 6/30/2023 5211080, exp. date 6/30/2023 5211364, exp. date 8/31/2024 5211365, exp. date 8/31/2024 5211367, exp. date 8/31/2024 5211366, exp. date 8/31/2024 5211575, exp. date 10/31/2024 5211576, exp. date 10/31/2024 5211694, exp. date 11/30/2024 5220066, exp. date 12/31/2024
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDADuloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by TowaApril 30, 2025
- FDADuloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-countApril 30, 2025
- FDADuloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (NDC 51991-747-90) Mfr. by: TowaJanuary 1, 2025
- FDADuloxetine Delayed-Release Capsules, USP, 60 mg, Rx Only, 90-count bottles (NDC 51991-748-90) Mfr. by: TowaJanuary 1, 2025
- FDAAlprazolam Tablets, USP, 0.25mg, CIV, packaged in: a) 100-count bottle (NDC 51991-0704-01), b) 500-countMarch 22, 2023
- FDAAlprazolam Tablets, USP, 1 mg, CIV, packaged in: a) 100-count bottle (NDC 51991-0706-01), b) 500-count bottleMarch 22, 2023
Questions about this recall
Was Alprazolam Tablets, USP, 0.5mg, CIV, packaged in: a) 100-count bottle (NDC 51991-0705-01), b) 500-count bottle (NDC 51991-0705-05) and c) 1,000-count bottle (NDC 51991-0705-10), Rx only, Manufactured by Centaur Pharmaceuticals PVT. LTD., Hinjewadi, Pune, INDIA, Distributed by: Breckenridge Pharmaceuticals, Inc., Berlin, CT 06037. recalled?
Yes. FDA published recall D-0459-2023 on March 22, 2023. Reported hazard: CGMP Deviations: Potential risk of Cross Contamination
What should I do if I have this product?
Voluntary: Firm initiated · Letter